Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Change in Cash (2017 - 2025)

Historic Change in Cash for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to -$15.4 million.

  • Vistagen Therapeutics' Change in Cash fell 6173.54% to -$15.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$27.3 million, marking a year-over-year increase of 4725.82%. This contributed to the annual value of -$52.0 million for FY2025, which is 15075.2% down from last year.
  • As of Q4 2025, Vistagen Therapeutics' Change in Cash stood at -$15.4 million, which was down 6173.54% from $13.8 million recorded in Q3 2025.
  • In the past 5 years, Vistagen Therapeutics' Change in Cash registered a high of $89.0 million during Q4 2023, and its lowest value of -$18.7 million during Q3 2024.
  • Moreover, its 5-year median value for Change in Cash was -$9.5 million (2021), whereas its average is -$3.1 million.
  • Its Change in Cash has fluctuated over the past 5 years, first crashed by 289423.48% in 2021, then skyrocketed by 96783.29% in 2023.
  • Vistagen Therapeutics' Change in Cash (Quarter) stood at -$9.9 million in 2021, then fell by 3.25% to -$10.2 million in 2022, then surged by 967.83% to $89.0 million in 2023, then plummeted by 110.71% to -$9.5 million in 2024, then plummeted by 61.74% to -$15.4 million in 2025.
  • Its Change in Cash was -$15.4 million in Q4 2025, compared to $13.8 million in Q3 2025 and -$18.1 million in Q2 2025.